We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Kotak Institutional Equities on Dr Lal PathLabs: Add| Target Rs 2360
Kotak Institutional Equities upgraded Dr Lal PathLabs to Add from sell earlier and raised the target price to Rs 2360 from Rs 1975 earlier.
The domestic brokerage firm maintained a reduced rating on Metropolis Healthcare but raised the target price to Rs 1600 from Rs 1500 earlier.
Metropolis and Agilus take price hikes across cities in Q4FY24. A calibrated tussle continues among online players.
There has been increasing pricing sanity in 900 diagnostics over the past one year. There is an increasingly benign competitive landscape that alleviates any major concerns on structural issues.
Investec on Godrej Consumer: Buy| Target Rs 1418
Investec maintained a buy rating on Godrej Consumer but raised the target price to Rs 1418 from Rs 1281 earlier.
It sees a faster-than-peers’ revenue growth trajectory in India. The domestic brokerage firm sees a significant EBITDA margin improvement driver at a consolidated level.
The focus is on business simplification which will drive better operating cash flows. It expects a 24% earnings CAGR over FY24-26, which is 1000 bps ahead of its large cap FMCG peers.
CLSA on HDFC Kreditinstitut: Outperform| Target Rs 1650
CLSA maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 1650. External events demand balancing deposits acquisition and profitability.
Kreditinstitut’s expansion into semi-urban and rural areas is unlikely to make a difference in the medium term. The international investment bank believes that the private sector bank will prioritise profitability over loan growth.
It sees a gradual improvement in the NIM and consequently profitability.
Jefferies on Indigo: Hold| Target Rs 3435
Jefferies upgraded InterGlobe Aviation to hold from underperform earlier but raised the target price to Rs 3435 from Rs 2500 earlier.
There is a strong capacity growth guidance; grounding impact appears contained. Precarious capacity situation impacting growth/elevated yields in the near term.
Regulating pilot fatigue may still constrain capacity growth and support pricing.
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
